Roger Li, MD, reviews how the NIAGARA, KEYNOTE-905, KEYNOTE-B15, and VOLGA trials are moving perioperative care for muscle-invasive bladder cancer beyond cisplatin-based chemotherapy and why the data should change which patients urologists refer for neoadjuvant therapy.
Roger Li, MD, explains why patients with MIBC fall away between TURBT and a medical oncology visit, how strong urologist–oncologist relationships speed the start of neoadjuvant therapy, and how newer non-cisplatin regimens are changing referral patterns and surgical timing.
Roger Li, MD, addresses the open questions surrounding adjuvant therapy after cystectomy, the urologist's role in recognizing treatment-related toxicities, and why multidisciplinary referral is the change most likely to deliver the full benefit of perioperative therapy.
